Hypermarcas (OTCMKTS:HYPMY) Stock Short Interest Report for October

Hypermarcas (OTCMKTS:HYPMY) was the recipient of a large increase in short interest during the month of October. As of October 30th, there was short interest totaling 8,208 shares, an increase of 390.0% from the October 15th total of 1,675 shares. Based on an average trading volume of 84,726 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the company’s stock are sold short.

Hypermarcas Stock Performance

HYPMY stock traded down $0.02 during midday trading on Friday, reaching $3.96. 11,560 shares of the company were exchanged, compared to its average volume of 46,635. The firm has a market capitalization of $2.79 billion, a price-to-earnings ratio of 7.62 and a beta of 0.78. The business has a 50-day moving average price of $4.62 and a two-hundred day moving average price of $4.40. Hypermarcas has a one year low of $3.39 and a one year high of $5.77. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.86 and a quick ratio of 1.26.

Hypermarcas (OTCMKTS:HYPMY) last announced its earnings results on Wednesday, November 11th. The company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.14 by $0.01. Hypermarcas had a net margin of 20.07% and a return on equity of 12.58%. The business had revenue of $473.13 million during the quarter, compared to the consensus estimate of $450.75 million. Equities research analysts forecast that Hypermarcas will post 0.50 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group upgraded shares of Hypermarcas to a “strong-buy” rating in a research note on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Hypermarcas presently has an average rating of “Buy”.

Hypermarcas Company Profile

Hypermarcas was a Brazilian consumer-products and pharmaceutical company that later adopted the name Hypera Pharma. The company refocused its operations on pharmaceuticals after divesting a number of businesses in other consumer-goods categories. Today, Hypera Pharma develops, manufactures and markets medicines in Brazil, including prescription drugs, over-the-counter products and branded generics. Its portfolio also includes vitamins and supplements, and it sells products under brands such as Neo Química and Mantecorp.